MedTrace Logo

Iron Supplementation and Eccentric Exercise

NCT02374619 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2015-04-14

No results posted yet for this study

Summary

Iron supplementation is very common in athletes, probably due to its catalytic role on the oxygen transport and optimal function of oxidative enzymes and proteins during exercise.

Iron is also characterized as a potent pro-oxidant, as it can lead to increased production of reactive oxygen and nitrogen species (RONS) that are involved in critical biological processes, such as gene expression, signal transduction and enzyme activity. In exercise, low levels of RONS are essential for optimal force production, whereas excessive production of RONS can cause contractile dysfunction, resulting in muscle weakness and fatigue. On the other hand, RONS are involved in signaling pathways and up-regulation of the expression of several genes, and therefore, RONS can provoke favorable effects such as training adaptations.

The purpose of the present study is to investigate the effect of iron supplementation on redox status, muscle damage and muscle performance after an acute bout of a valid muscle damaging eccentric exercise model in adults and children.

Conditions

  • Muscle Damage
  • Oxidative Stress

Interventions

DIETARY_SUPPLEMENT

Iron supplement Resoferon Ferrous Sulfate

Oral supplementation with one tablet of iron supplement \[Resoferon Ferrous Sulfate 125 (37) mg\]

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • University of Thessaly

    lead OTHER

Principal Investigators

  • Athanasios Z Jamurtas, Dr · University of Thessaly

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
10 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-10-31
Completion
2013-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02374619 on ClinicalTrials.gov